Login to Your Account



Multiple Layers of Targeting

BIND Goes Small to Make it Big With a Next-Gen Nanoparticle

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, January 28, 2013

Liposome nanoparticles have been in existence for nearly two decades. Doxil (doxorubicin liposomal), developed by Sequus Pharmaceuticals Inc., gained FDA approval in 1995. But liposomes have limited use because it's hard to target them to specific tissue and there are very few drugs that can be loaded into and released from liposomes.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription